Alphyn Biologics, Inc.

In case you missed it, interim results of a Phase 2a study of Zabalafin Hydrogel demonstrated that the topical treatment clinically improved itch and quality of life in children and adults with #atopicdermatitis. The results, which were presented at the European Academy of Dermatology and Venereology, suggest Zabalafin Hydrogel could be a safe and effective treatment for both AD skin non-infected and AD skin infected. Thanks to Healio and Gabrielle Grasso (Capaldo) for covering the news https://lnkd.in/gsp2gvf9 Check out our poster here http://bit.ly/3Y654WR #clinicaltrials #dermatology

Alphyn CEO Neal Koller will be at BIO Investor Forum this week for partnering meetings and to present on the latest with Alphyn and our Zabalafin Hydrogel for atopic dermatitis. Following excellent results in our Phase 2a trial, we're preparing for global Phase 2b trials next year. If you're at the conference, stop by Alphyn's presentation Tuesday at 1:45 p.m. in the California Room or reach out if you'd like to learn more. #atopicdermatitis #dermatology #venturecapital

We’re headed to New York this week to present at the MedInvest Biotech & Pharma Investor Conference. CEO Neal Koller will provide an overview of our successful Phase 2a clinical trials in #atopicdermatitis, our work in epidermolysis bullosa, and what’s in store for the year ahead. #venturecapital #clinicaltrials #dermatology #epidermolysisbullosa

It was great to present this week at the New York Venture Summit and to have the opportunity to share more about the work we’re doing to advance novel therapeutics for #atopicdermatitis and epidermolysis bullosa. #dermatology #epidermolysisbullosa #clinicaltrials https://lnkd.in/gRirN5ED

Alphyn to Present Poster on Zabalafin Hydrogel Clinical Results at European Academy of Dermatology and Venereology Congress 2024 https://lnkd.in/gSEVKGhX ANNAPOLIS, Md., Aug. 27, 2024 /PRNewswire/ — Alphyn Biologics, Inc., a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that data from its Phase 2a human clinical trial of Zabalafin Hydrogel (AB-101a) in atopic [...]

We’re excited to be presenting data from our Phase 2a clinical trial of Zabalafin Hydrogel (AB-101a) in #atopicdermatitis (AD) next month at the European Academy of Dermatology and Venereology Congress 2024 in Amsterdam. The first-in-human trial was designed to assess the most important treatment considerations for AD – itch and quality of life improvement, as well as the safety and efficacy of Zabalafin Hydrogel. Come check us out if you’re at #EADVCongress or reach out if you want to learn more. https://lnkd.in/gmypgfrK #clinicaltrials #dermatology

Great to be featured today as an alum of Opus8, Inc.'s CONNECTpreneur event this summer. Check out the video of Alphyn CEO Neal Koller presenting.

We’re excited to announce that we’ve received a notice of claims allowance from the U.S. Patent and Trademark Office covering compositions and methods of use for the drug formulation of Zabalafin Hydrogel (AB-101a) for #atopicdermatitis. Zabalafin Hydrogel is our lead product candidate and is being developed as the first therapeutic for AD to directly treat AD’s itch, directly treat bacteria that are increasingly thought to cause AD’s inflammation and flares and cause infected AD skin, and directly treat AD’s inflammation. https://lnkd.in/guiFxDwf #dermatology #eczema #patents

Did you know that even with current #atopicdermatitis treatments more than half of adults with AD are still worried about long-term use, and more than half have found a treatment to be ineffective, according to the National Eczema Association. What’s more, 44 percent have discontinued a treatment. Learn more here https://lnkd.in/d6pKjTTQ #dermatology #eczema

We’re headed to 49th Annual Meeting of the Society for Pediatric Dermatology in Toronto this week! Super excited to be presenting a poster on the Phase 2 trial of Zabalafin hydrogel (AB-101a) for atopic dermatitis, specifically focusing on the pediatric population results related to itch and quality of life. https://lnkd.in/g6bW4Wtd #atopicdermatitis #dermatology #clinicaltrials